British inventor, Paul Hope, made it his mission to find a way to prevent pandemic deaths after his own grandfather died of the Spanish Flu in 1919. This latest discovery builds on over 10 years of work by Virustatic Limited and a team of international biochemists, material scientists and virologists.

Laboratory tests have proven that the Viruferrin™ coated material, developed originally for flu pandemics, also captures 99% of SARS-CoV-2, the virus that causes COVID-19.

The Virustatic Shield provides a comfortable fit following the contours of your face to block and capture virus-laden coughs, sneezes and infective particles and droplets in your breath or the air around you.

If you, or someone else, has become infected with COVID-19, as they breathe out through the Virustatic Shield face covering, it will protect other people by disabling the infectious particles that are shed, even if the person wearing the Virustatic Shield face covering does not realise they are infectious.

In addition, the anti-viral coating of the Virustatic Shield face covering disables up to 99% of any infectious material with which it comes into contact, with repeated tests showing that less than 1% of the virus is redeposited on to your fingers or other surfaces. Therefore, unlike other masks, it is safe to touch, adjust and handle during and after wearing, without contaminating your hands. Unlike other single-use masks that have a limited lifetime, the Virustatic Shield face covering provides lasting protection. It can be washed three times^*, whilst retaining its 99% protection.

It is the product of 10 years of pioneering protein and material science research, led by UK biotech firm Virustatic Ltd and is accredited with ISO:18184, an international standard for anti-viral textiles.